Skip to main content

Advertisement

Table 4 Median survival (months) in the 145 patients with "early" HCC of the internal validation analysis according to the type of treatment.

From: Early and very early hepatocellular carcinoma: when and how much do staging and choice of treatment really matter? A multi-center study

Type of treatment N Median survival (months) CI 95%
OLTx 5 79 66.211 91.556
RESECTION 17 45 34,327 53,254
RFTA 46 45 40.394 51.247
PEI 16 37 14.384 59.616
TACE 41 44 34.518 53.482
PEI + TACE 10 36 32.006 39.994
BSC 10 12 9.078 14.922
Total 145 45 40.708 49.292
  1. OLTx: orthotopic liver transplantation; RFTA: radiofrequency-mediated thermal ablation; PEI: percutaneous ethanol injection; TACE: transcatheter arterial chemoembolization; BSC: best supportive care.
  2. The difference in survival among treatment groups is statistically significant (p = 0,003). In the COX multivariate analysis however only age and Child-Pugh class (p = 0.025 and p = 0.011, respectively) were selected as independent predictors of survival.